Comparative Pharmacology
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus QDOLO.
METHADONE HYDROCHLORIDE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; also NMDA receptor antagonist and serotonin/norepinephrine reuptake inhibitor.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Oral: 20-30 mg daily for induction, then 20-120 mg daily for maintenance; IV: 2.5-10 mg every 8-12 hours for acute pain, titrated; IM/SC: same as IV. Frequency: daily for maintenance, every 8-12 hours for pain.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal half-life 24-36 hours (range 13-50 hours) for active l-isomer; clinical context: once-daily dosing possible but cautious due to prolonged QT interval risk.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal (80-90% as methadone and metabolites; ~30% unchanged), biliary/fecal (minor ~10%)
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist